Skip to content

Study · Animal study (in vivo) · rat · 2017

2 results

Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME.

Drmic D, Kolenc D, Ilic S, Bauk L, Sever M, Zenko Sever A, Luetic K, Suran J, Seiwerth S, Sikiric P

World journal of gastroenterology1 Aug 2017Cited by 48 (Europe PMC)

PMID28839430 (opens in a new tab)PMCIDPMC5550779 (opens in a new tab)DOI10.3748/wjg.v23.i29.5304 (opens in a new tab)PepBankPUB-28839430
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats given high-dose celecoxib, BPC‑157 counteracted the noxious effects of celecoxib on gastric, liver and brain lesions.

    In plain wordsIn rats given a high celecoxib dose, BPC‑157 reduced stomach, liver and brain damage.

    Peptide
    BPC-157
    Outcome
    DecreaseCelecoxib-induced gastric, liver and brain lesions
    Study

    ratn: not reported in source

    celecoxib-induced toxicity with NOS blockade
    Outcome group
    Gastrointestinal protection · Whole body
    Studied dose
    10 μg/kg, 10 ng/kg, 1 ng/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    BPC 157 may equally counteract both COX-2 inhibition (counteracting the noxious effects of celecoxib on all lesions)
    2 context sentences
    Summary · context
    An even more complete antagonization was identified with BPC 157 (at both 24 h and 48 h).
    Summary · context
    Gastrointestinal, liver, and brain lesions and liver enzyme serum values in rats were assessed at 24 h and 48 h thereafter.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats given celecoxib and L-NAME, BPC‑157 counteracted the added noxious effects of NOS blockade, in all BPC‑157 groups.

    In plain wordsIn rats given celecoxib plus L-NAME, BPC‑157 reduced the added damage.

    Peptide
    BPC-157
    Outcome
    DecreaseLesions after celecoxib plus L-NAME (NOS blockade)
    Study

    ratn: not reported in source

    celecoxib-induced toxicity with NOS blockade
    Outcome group
    Gastrointestinal protection · Whole body
    Studied dose
    10 μg/kg, 10 ng/kg, 1 ng/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    additional NOS blockade (equally counteracting the noxious effects of celecoxib + L-NAME).
    2 context sentences
    Summary · context
    A beneficial effect was evident on all the increasingly negative effects of celecoxib and L-NAME application and in all the BPC 157 groups (L-arginine + BPC 157; L-NAME + BPC 157; L-NAME + L-arginine + BPC 157).
    Summary · context
    Gastrointestinal, liver, and brain lesions and liver enzyme serum values in rats were assessed at 24 h and 48 h thereafter.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.